Investors signalled that they were pleased with Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) most recent earnings report. This reaction by the market reaction is understandable when looking at headline profits and we have found some further encouraging factors.
The Impact Of Unusual Items On Profit
For anyone who wants to understand Regeneron Pharmaceuticals' profit beyond the statutory numbers, it's important to note that during the last twelve months statutory profit was reduced by US$1.1b due to unusual items. It's never great to see unusual items costing the company profits, but on the upside, things might improve sooner rather than later. We looked at thousands of listed companies and found that unusual items are very often one-off in nature. And, after all, that's exactly what the accounting terminology implies. If Regeneron Pharmaceuticals doesn't see those unusual expenses repeat, then all else being equal we'd expect its profit to increase over the coming year.
That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.
Our Take On Regeneron Pharmaceuticals' Profit Performance
Because unusual items detracted from Regeneron Pharmaceuticals' earnings over the last year, you could argue that we can expect an improved result in the current quarter. Because of this, we think Regeneron Pharmaceuticals' earnings potential is at least as good as it seems, and maybe even better! And on top of that, its earnings per share have grown at 25% per year over the last three years. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. In light of this, if you'd like to do more analysis on the company, it's vital to be informed of the risks involved. You'd be interested to know, that we found 1 warning sign for Regeneron Pharmaceuticals and you'll want to know about it.
This note has only looked at a single factor that sheds light on the nature of Regeneron Pharmaceuticals' profit. But there are plenty of other ways to inform your opinion of a company. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.